CAPTURE - Cancer and COVID-19 antiviral response study

Project summary:

CAPTURE is a longitudinal, prospective cohort study in patient with cancer investigating immune responses after SARS-CoV-2 infection or COVID-19 vaccination. CAPTURE enrols patients with all types of cancer (blood and solid cancers) and all stages of disease. In the first phase of the study, we have recruited patients with cancer and with confirmed SARS-CoV-2 infection or without clinical evidence of infection and longitudinally collected samples at each clinical visit. This allowed us to longitudinally monitor immune responses to infection in patients with asymptomatic to severe COVID-19. Within the second phase, we then investigated immune response of 585 patients with different types of cancer after receiving a first and second dose of the COVID-19 vaccine (Pfizer-BioNTech or Oxford-AstraZeneca). All patients were followed-up longitudinally to analyse duration of immune response, identify patients with breakthrough infections, and analyse immune responses in those patients with cancer eligible for a third and fourth vaccine dose.



The Royal Marsden Cancer Charity

Leader researcher:

Dr Samra Turajlic

Lead institution:

The Royal Marsden NHS Foundation Trust & The Francis Crick Institute

Vaccine type:


Recruitment for clinical trial open: